Drug Profile
Research programme: gastrointestinal disease and pain therapies - AstraZeneca
Alternative Names: AZD 5329Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gastrointestinal disorders; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in United Kingdom
- 07 Dec 2007 A lead candidate from this research programme, AZD 2066, enters clinical development